Locations
Cleveland, OH, USA
industry
Biotechnology · DeepTech · Health
Size
11-50 employees
Stage
Other
founded in
2016
Haima Therapeutics is a pre-clinical stage biopharma company developing cell-inspired therapies for the treatment of bleeding and various blood-related diseases. Their lead technology, Syntho Plate, is a novel, fully-synthetic hemostatic agent designed to mitigate bleeding by enhancing the body's natural clotting mechanisms. The company differentiates itself through its platelet-inspired platform technology, which allows for tunable and specific activity, easy large-scale manufacturing, and a long shelf-life. With a focus on addressing critical medical needs, Haima Therapeutics is positioned to make significant impacts in the biopharma sector, particularly in trauma and surgical care.
Something looks off?